Skip to main content

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

Completed · Phase 3 · NCT04713592

Conditions: Psoriasis

At a glance

Research payments reported, 2025
$26,903
U.S. investigators named
2
Sites paid
2
Planned or actual enrollment
174

About the trial

Sponsor
AbbVie
Tested
Placebo for Risankizumab (drug), Risankizumab (drug)
Dates
Started 2021-02-26; completion 2023-04-20
Results posted
Yes

Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. Palmoplantar (non-pustular) plaque psoriasis (PPPsO) represents a localized form of psoriasis in palms and soles. This study will evaluate how safe risankizumab is for the treatment of plaque psoriasis with palmoplantar involvement and to assess change in disease symptoms. Risankizumab is an approved drug for the treatment of psoriasis. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1…

From ClinicalTrials.gov, last updated 2024-06-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $26,903 in research payments for this study in 2025 (2 payments).

Products named: Skyrizi

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.